Back to Browse Journals » Vascular Health and Risk Management » Volume 7

Differential clinical profile of candesartan compared to other angiotensin receptor blockers

Authors Cernes R, Mashavi M, Zimlichman R

Published 12 December 2011 Volume 2011:7 Pages 749—759

DOI https://dx.doi.org/10.2147/VHRM.S22591

Review by Single-blind

Peer reviewer comments 4

Relu Cernes1,2, Margarita Mashavi1,3, Reuven Zimlichman1,3
1The Brunner Institute for Cardiovascular Research, Wolfson Medical Center and Tel Aviv University, Tel Aviv, Israel; 2Department of Nephrology, Wolfson Medical Center, Holon, Israel; 3Department of Medicine, Wolfson Medical Center, Holon, Israel

Abstract: The advantages of blood pressure (BP) control on the risks of heart failure and stroke are well established. The renin-angiotensin system plays an important role in volume homeostasis and BP regulation and is a target for several groups of antihypertensive drugs. Angiotensin II receptor blockers represent a major class of antihypertensive compounds. Candesartan cilexetil is an angiotensin II type 1 (AT[1]) receptor antagonist (angiotensin receptor blocker [ARB]) that inhibits the actions of angiotensin II on the renin-angiotensin-aldosterone system. Oral candesartan 8–32 mg once daily is recommended for the treatment of adult patients with hypertension. Clinical trials have demonstrated that candesartan cilexetil is an effective agent in reducing the risk of cardiovascular mortality, stroke, heart failure, arterial stiffness, renal failure, retinopathy, and migraine in different populations of adult patients including patients with coexisting type 2 diabetes, metabolic syndrome, or kidney impairment. Clinical evidence confirmed that candesartan cilexetil provides better antihypertensive efficacy than losartan and is at least as effective as telmisartan and valsartan. Candesartan cilexetil, one of the current market leaders in BP treatment, is a highly selective compound with high potency, a long duration of action, and a tolerability profile similar to placebo. The most important and recent data from clinical trials regarding candesartan cilexetil will be reviewed in this article.

Keywords: angiotensin receptor blockers, candesartan, candesartan cilexetil, clinical trials, efficacy studies, safety, blood pressure

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers

ElHalawani H, Abdel-Rahman O

Therapeutics and Clinical Risk Management 2015, 11:1123-1132

Published Date: 28 July 2015

Current and emerging management options for patients with Morquio A syndrome

Algahim MF, Almassi GH

Therapeutics and Clinical Risk Management 2013, 9:45-53

Published Date: 11 February 2013

Critical review of cancer risk associated with angiotensin receptor blocker therapy

Wuerzner G, Burnier M, Waeber B

Vascular Health and Risk Management 2011, 7:741-747

Published Date: 12 December 2011

Effects of smoking cessation on central blood pressure and arterial stiffness

Takami T, Saito Y

Vascular Health and Risk Management 2011, 7:633-638

Published Date: 20 October 2011

Pre-eclampsia: pathophysiology, diagnosis, and management

Uzan J, Carbonnel M, Piconne O, Asmar R, Ayoubi J-M

Vascular Health and Risk Management 2011, 7:467-474

Published Date: 19 July 2011

Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation

Sezer ED, Sozmen EY, Nart D, Onat T

Vascular Health and Risk Management 2011, 7:333-343

Published Date: 1 June 2011

Novel drug-eluting stents in the treatment of de novo coronary lesions

Davide Capodanno, Fabio Dipasqua, Corrado Tamburino

Vascular Health and Risk Management 2011, 7:103-118

Published Date: 25 February 2011

Effects on cardiovascular disease risk of a web-based health risk assessment with tailored health advice: a follow-up study

Ersen B Colkesen, Bart S Ferket, Jan GP Tijssen, et al

Vascular Health and Risk Management 2011, 7:67-74

Published Date: 9 February 2011